Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441637 | 0.87 | NPSR1 (0.36) | NPSR1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL29441655 | 0.80 | NPSR1 (0.36) | NPSR1L3MBTL1ALDH1A1KDM4ELMNA | |
| SCHEMBL4237820 | 0.80 | CYP1A2 (0.40) | L3MBTL1ALDH1A1KDM4ECYP1A2TP53 | |
| SCHEMBL31228324 | 0.79 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL23302080 | 0.75 | MEN1 (0.32) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29112659 | 0.74 | NPSR1 (0.38) | NPSR1L3MBTL1ALDH1A1KDM4ELMNA | |
| SCHEMBL23214244 | 0.74 | KCNH2 (0.35) | NPSR1ALDH1A1KDM4ECYP1A2HPGD | |
| SCHEMBL26061187 | 0.73 | NPSR1 (0.36) | NPSR1L3MBTL1ALDH1A1KDM4ELMNA | |
| SCHEMBL31696636 | 0.73 | PKM (0.40) | NPSR1L3MBTL1ALDH1A1KDM4ELMNA | |
| SCHEMBL9826880 | 0.72 | SMN1; SMN2 (0.51) | NPSR1ALDH1A1LMNASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114630822-B | Biaryl dihydroorotate acid dehydrogenase inhibitors | 詹森生物科技公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4041714-B1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117120430-A | MK2 inhibitors and uses thereof | 新特拉有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | NOVIRA THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| EP-4051672-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114650988-A | Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases | 詹森生物科技公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114630822-A | Biaryl dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022070068-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022053453-A1 | AZOLE CARBOXAMIDE AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021084500-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084500-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021070132-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | NPSR1 3861/4885L3MBTL1 4666/4885ALDH1A1 4145/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | NPSR1 3861/4885L3MBTL1 4666/4885ALDH1A1 4145/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | NPSR1 3861/4885L3MBTL1 4666/4885ALDH1A1 4145/4885 |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | NPSR1 4442/4885L3MBTL1 1251/4885ALDH1A1 54/4885 |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | DHODH, NQO2, DPYD | NPSR1 4281/4885L3MBTL1 2129/4885ALDH1A1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.